Skip to main navigation Skip to search Skip to main content

A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer

  • Paul A Foster
  • , Simon P Newman
  • , Mathew P Leese
  • , Sonia Bernetiere
  • , Christian Diolez
  • , Jose Camara
  • , Beatrice Hacher
  • , Marie-Madeleine Baronnet
  • , Tauhid Ali
  • , Barry V L Potter
  • , Michael J Reed
  • , Atul Purohit

    Research output: Contribution to journal › Article › peer-review

    11 Citations (Scopus)

    Abstract

    There is a continued need for orally bioavailable anticancer compounds that exhibit good efficacy against breast cancer. STX140, a derivative of 2-methoxyestradiol (2-MeOE2), has been shown to have excellent oral bioavailability and significantly reduces tumor growth. A new micronized formulation of STX140 has now been developed and its pharmacokinetics (PK) in rats and effect on MDA-MB-231 breast cancer growth in nude mice was investigated.
    Original languageEnglish
    Pages (from-to)577-81
    Number of pages5
    JournalAnticancer research
    Volume28
    Issue number2A
    Publication statusPublished - 2008

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer'. Together they form a unique fingerprint.

    Cite this